SCHEMBL5135975

SCHEMBL5135975

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1c(F)cccc1F

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
C5AR1 P21730 1/20 0.43
TSHR P16473 4/20 0.41
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CRHR1 P34998 3/20 0.37
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE4B Q07343 2/20 0.36
NR1H3 Q13133 1/20 0.36
TP53 P04637 1/20 0.34
CYP3A4 P08684 2/20 0.34
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136067 0.93 KDM4E (0.41) KDM4EC5AR1TSHRALDH1A1SMN1; SMN2
SCHEMBL649626 0.92 C5AR1 (0.41) KDM4EC5AR1TSHRALDH1A1SMN1; SMN2
SCHEMBL5074878 0.91 TSHR (0.42) KDM4EC5AR1TSHRALDH1A1CRHR1
SCHEMBL651094 0.90 TSHR (0.50) KDM4EC5AR1TSHRALDH1A1SMN1; SMN2
SCHEMBL5136299 0.90 C5AR1 (0.45) KDM4EC5AR1TSHRALDH1A1SMN1; SMN2
SCHEMBL647986 0.89 C5AR1 (0.43) KDM4EC5AR1TSHRALDH1A1SMN1; SMN2
SCHEMBL5072370 0.89 C5AR1 (0.47) KDM4EC5AR1TSHRALDH1A1HPGD
SCHEMBL5134701 0.88 KDM4E (0.39) KDM4EC5AR1TSHRALDH1A1CRHR1
SCHEMBL5136166 0.88 C5AR1 (0.43) KDM4EC5AR1TSHRALDH1A1CRHR1
SCHEMBL5135911 0.87 TSHR (0.39) KDM4EC5AR1TSHRALDH1A1CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed